Medpace Holdings, Inc. (MEDP) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Medpace’s revenue went from $422M in fiscal 2016 to $2.5B in fiscal 2025, growth of about 22.0% a year.
Net income in fiscal 2025 was $451M, a net margin of 17.8%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $2.8B and net income $518M.
Free cash flow was $682M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 19% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8B | $2.5B | $2.1B | $1.9B | $1.5B | $1.1B | $926M | $861M | $705M | $436M | $422M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $607M | $535M | $447M | $337M | $279M | $199M | $167M | $127M | $101M | $65M | $52M |
| Net income | $518M | $451M | $404M | $283M | $245M | $182M | $145M | $100M | $73M | $39M | $13M |
| EPS (diluted) | $18.01 | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 | $3.84 | $2.67 | $1.97 | $0.98 | $0.37 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +20.0% | +11.8% | +29.2% | +27.8% | +23.4% | +7.5% | +22.2% | +61.6% | +3.5% | +17.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $723M | $713M | $609M | $433M | $388M | $263M | $259M | $202M | $157M | $97M | $92M |
| Capital spending | -$55M | -$31M | -$37M | -$37M | -$37M | -$28M | -$31M | -$18M | -$16M | -$12M | -$14M |
| Free cash flow | $668M | $682M | $572M | $397M | $351M | $235M | $227M | $184M | $141M | $86M | $78M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $295M | $917M | $170M | $144M | $848M | $62M | $98M | $0 | $0 | $156M | $0 |
| Stock-based pay | $22M | $35M | $26M | $21M | $21M | $14M | $14M | $21M | $6M | $4M | $10M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $497M | $669M | $245M | $28M | $461M | $278M | $132M | $23M | $26M | $37M |
| Debt | — | $137M | $150M | $164M | $208M | $147M | $131M | $56M | $80M | $223M | $165M |
| Equity | — | $459M | $826M | $559M | $386M | $953M | $806M | $726M | $599M | $509M | $611M |
| Total assets | — | $2.0B | $2.1B | $1.7B | $1.4B | $1.7B | $1.4B | $1.1B | $968M | $951M | $979M |
| Shares (diluted) | 28M | 30M | 32M | 32M | 34M | 38M | 38M | 38M | 37M | 40M | 36M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 21.4% | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% | 18.0% | 14.8% | 14.3% | 14.9% | 12.4% |
| Net margin | 18.2% | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | 15.7% | 11.7% | 10.4% | 9.0% | 3.2% |
| FCF margin | 23.5% | 27.0% | 27.1% | 21.0% | 24.1% | 20.6% | 24.6% | 21.4% | 20.0% | 19.6% | 18.6% |
| ROIC | — | 74.7% | 38.9% | 39.2% | 40.7% | 16.3% | 15.4% | 13.1% | 11.6% | 6.1% | 4.1% |
| ROE | — | 98.3% | 49.0% | 50.6% | 63.5% | 19.1% | 18.0% | 13.8% | 12.2% | 7.7% | 2.2% |
Frequently asked questions
What is Medpace’s annual revenue?
$2.5B in fiscal 2025 and $2.8B over the twelve months to September 30, 2026.
How much profit does Medpace make?
Net income was $451M in fiscal 2025 (net margin 17.8%).
Is Medpace’s revenue growing?
Yes: revenue rose 20.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.